English

Oncoinvent ASA

ESEF

Report (type unavailable) · filed 2026-10-21

Annual consolidated revenue for 2025: about NOK 23.04M, using the latest reported figures. The previous period, 2024, was about NOK 2.729M.

Inspect reported changes Compare with another company Historical disclosures Segments

Watchlist

Latest fiscal year

Revenue

23 million NOK

2025 · NOK

Exact inputs and evidence

Revenue: 23037000 NOK Source

Operating margin

-687.29%

2025 · %

Exact inputs and evidence

Operating Income: -158330000 NOK Source
Revenue: 23037000 NOK Source

Operating cash flow

-130 million NOK

2025 · NOK

Exact inputs and evidence

Operating Cash Flow: -129872000 NOK Source

Free cash flow

-130 million NOK

2025 · NOK

Exact inputs and evidence

Operating Cash Flow: -129872000 NOK Source
Capital Expenditure: 119000 NOK Source

Cash and cash equivalents: 178 million NOK 2025-12-31 Source
Exact value

177604000 NOK
Long-term debt including current maturities: Not available
Shares outstanding: Not available

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-10-21.

Financial data available through: 2025-12-31.

Coverage by financial measure

Revenue: 6 of 11 periods available· newest 2025-12-31
Operating income: 6 of 11 periods available· newest 2025-12-31
net income: No compatible figures in this window
Operating cash flow: 6 of 11 periods available· newest 2025-12-31
Capital expenditure: 3 of 11 periods available· newest 2025-12-31
Total assets: 6 of 11 periods available· newest 2025-12-31
Total liabilities: 6 of 11 periods available· newest 2025-12-31
Current assets: 6 of 11 periods available· newest 2025-12-31
Current liabilities: 6 of 11 periods available· newest 2025-12-31
Cash and cash equivalents: 6 of 11 periods available· newest 2025-12-31
long term debt: No compatible figures in this window
shares outstanding: No compatible figures in this window

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+744.2%

Prior period

NOK 2.73 million

2024-01-01 – 2024-12-31
Current period

NOK 23.04 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

23037000 − 2729000 = 20308000 NOK

2729000 NOK · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
23037000 NOK · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · Oncoinvent ASA · 2025-12-31 Oncoinvent ASA (esef:213800TYYFXKYF3V2A23) Year-over-year change in Revenue: 20308000 NOK Concept: fundies:Revenue Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-09T13:35:15Z Snapshot: 6eaa3e69e995bfa95c892bf088f139d4f0c61751cb70f2c4c98682d45b353da8 Dimensions: Consolidated View: https://fundies.io/companies/esef/213800TYYFXKYF3V2A23?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 23037000 NOK (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/213800TYYFXKYF3V2A23/2025-12-31/ESEF/NO/0/213800TYYFXKYF3V2A23-2025-12-31.zip#9714059 Filing: 213800TYYFXKYF3V2A23-2025-12-31-ESEF-NO-0 Input fundies:Revenue: 2729000 NOK (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/213800TYYFXKYF3V2A23/2025-12-31/ESEF/NO/0/213800TYYFXKYF3V2A23-2025-12-31.zip#9714326 Filing: 213800TYYFXKYF3V2A23-2025-12-31-ESEF-NO-0
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−NOK 41.93 million

Prior period

−NOK 87.94 million

2024-01-01 – 2024-12-31
Current period

−NOK 129.87 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-129872000 − -87943000 = -41929000 NOK

-87943000 NOK · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-129872000 NOK · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Oncoinvent ASA · 2025-12-31 Oncoinvent ASA (esef:213800TYYFXKYF3V2A23) Year-over-year change in Operating cash flow: -41929000 NOK Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-09T13:35:15Z Snapshot: 6eaa3e69e995bfa95c892bf088f139d4f0c61751cb70f2c4c98682d45b353da8 Dimensions: Consolidated View: https://fundies.io/companies/esef/213800TYYFXKYF3V2A23?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -129872000 NOK (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/213800TYYFXKYF3V2A23/2025-12-31/ESEF/NO/0/213800TYYFXKYF3V2A23-2025-12-31.zip#9898032 Filing: 213800TYYFXKYF3V2A23-2025-12-31-ESEF-NO-0 Input fundies:OperatingCashFlow: -87943000 NOK (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/213800TYYFXKYF3V2A23/2025-12-31/ESEF/NO/0/213800TYYFXKYF3V2A23-2025-12-31.zip#9898340 Filing: 213800TYYFXKYF3V2A23-2025-12-31-ESEF-NO-0
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-93.4%

Prior period

NOK 1.8 million

2024-01-01 – 2024-12-31
Current period

NOK 119,000

2025-01-01 – 2025-12-31

Exact inputs and evidence

119000 − 1802000 = -1683000 NOK

1802000 NOK · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
119000 NOK · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · Oncoinvent ASA · 2025-12-31 Oncoinvent ASA (esef:213800TYYFXKYF3V2A23) Year-over-year change in Capital expenditure: -1683000 NOK Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-09T13:35:15Z Snapshot: 6eaa3e69e995bfa95c892bf088f139d4f0c61751cb70f2c4c98682d45b353da8 Dimensions: Consolidated View: https://fundies.io/companies/esef/213800TYYFXKYF3V2A23?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 119000 NOK (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/213800TYYFXKYF3V2A23/2025-12-31/ESEF/NO/0/213800TYYFXKYF3V2A23-2025-12-31.zip#9902073 Filing: 213800TYYFXKYF3V2A23-2025-12-31-ESEF-NO-0 Input fundies:CapitalExpenditure: 1802000 NOK (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/213800TYYFXKYF3V2A23/2025-12-31/ESEF/NO/0/213800TYYFXKYF3V2A23-2025-12-31.zip#9902420 Filing: 213800TYYFXKYF3V2A23-2025-12-31-ESEF-NO-0
The citation records this snapshot. The page link may show a newer release later.

Comparable inputs unavailable for: Net income.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2025 2025-01-01 – 2025-12-31

Revenue NOK 23.04 million 100% of revenue
Operating costs Derived NOK 181.37 million 787% of revenue
Operating income −NOK 158.33 million −687% of revenue
Tax, interest and other Derived Unavailable An input is unavailable.
Net income Unavailable An input is unavailable.

Cash

Operating cash flow −NOK 129.87 million −564% of revenue
Capital expenditure NOK 119,000 0.5% of revenue
Free cash flow Derived −NOK 129.99 million −564% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2020 Not shown: operating income or net income is not reported.
2021 Not shown: operating income or net income is not reported.
2022 Not shown: operating income or net income is not reported.
2023 Not shown: operating income or net income is not reported.
2024 Not shown: operating income or net income is not reported.
2025 Not shown: operating income or net income is not reported.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2020 2020-01-01 – 2020-12-31	601000	261692000 Derived	-261091000	Unavailable	Unavailable	-234357000 Derived	Source 2020-01-01 – 2020-12-31: 601000 NOK Inspect Revenue Open source 2020-01-01 – 2020-12-31: -261091000 NOK Inspect Operating Income Open source 2020-01-01 – 2020-12-31: -234290000 NOK Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 67000 NOK Inspect Capital Expenditure Open source
2021 2021-01-01 – 2021-12-31	774000	315238000 Derived	-314464000	Unavailable	Unavailable	Unavailable	Source 2021-01-01 – 2021-12-31: 774000 NOK Inspect Revenue Open source 2021-01-01 – 2021-12-31: -314464000 NOK Inspect Operating Income Open source 2021-01-01 – 2021-12-31: -303340000 NOK Inspect Operating Cash Flow Open source
2022 2022-01-01 – 2022-12-31	389000	306024000 Derived	-305635000	Unavailable	Unavailable	Unavailable	Source 2022-01-01 – 2022-12-31: 389000 NOK Inspect Revenue Open source 2022-01-01 – 2022-12-31: -305635000 NOK Inspect Operating Income Open source 2022-01-01 – 2022-12-31: -288231000 NOK Inspect Operating Cash Flow Open source
2023 2023-01-01 – 2023-12-31	354000	192173000 Derived	-191819000	Unavailable	Unavailable	Unavailable	Source 2023-01-01 – 2023-12-31: 354000 NOK Inspect Revenue Open source 2023-01-01 – 2023-12-31: -191819000 NOK Inspect Operating Income Open source 2023-01-01 – 2023-12-31: -225101000 NOK Inspect Operating Cash Flow Open source
2024 2024-01-01 – 2024-12-31	2729000	143747000 Derived	-141018000	Unavailable	Unavailable	-89745000 Derived	Source 2024-01-01 – 2024-12-31: 2729000 NOK Inspect Revenue Open source 2024-01-01 – 2024-12-31: -141018000 NOK Inspect Operating Income Open source 2024-01-01 – 2024-12-31: -87943000 NOK Inspect Operating Cash Flow Open source 2024-01-01 – 2024-12-31: 1802000 NOK Inspect Capital Expenditure Open source
2025 2025-01-01 – 2025-12-31	23037000	181367000 Derived	-158330000	Unavailable	Unavailable	-129991000 Derived	Source 2025-01-01 – 2025-12-31: 23037000 NOK Inspect Revenue Open source 2025-01-01 – 2025-12-31: -158330000 NOK Inspect Operating Income Open source 2025-01-01 – 2025-12-31: -129872000 NOK Inspect Operating Cash Flow Open source 2025-01-01 – 2025-12-31: 119000 NOK Inspect Capital Expenditure Open source

Amounts are exact, in NOK.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

NOK 23M 2025

Values and sources

Revenue values and source evidence
Period	Series	Value(NOK)	Source evidence
20202020-12-31	Revenue	601000	Revenue: 601000 Open source
20212021-12-31	Revenue	774000	Revenue: 774000 Open source
20222022-12-31	Revenue	389000	Revenue: 389000 Open source
20232023-12-31	Revenue	354000	Revenue: 354000 Open source
20242024-12-31	Revenue	2729000	Revenue: 2729000 Open source
20252025-12-31	Revenue	23037000	Revenue: 23037000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

744.2% 2025

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Year over year	No prior comparable period	Revenue: 601000 Open source
20212021-12-31	Year over year	28.8%	Revenue: 774000 Open source Revenue: 601000 Open source
20222022-12-31	Year over year	-49.7%	Revenue: 389000 Open source Revenue: 774000 Open source
20232023-12-31	Year over year	-9%	Revenue: 354000 Open source Revenue: 389000 Open source
20242024-12-31	Year over year	670.9%	Revenue: 2729000 Open source Revenue: 354000 Open source
20252025-12-31	Year over year	744.2%	Revenue: 23037000 Open source Revenue: 2729000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -687.3% 2025

Free cash flow margin -564.3% 2025

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Operating margin	-43,442.8%	Operating Income: -261091000 Open source Revenue: 601000 Open source
20212021-12-31	Operating margin	-40,628.4%	Operating Income: -314464000 Open source Revenue: 774000 Open source
20222022-12-31	Operating margin	-78,569.4%	Operating Income: -305635000 Open source Revenue: 389000 Open source
20232023-12-31	Operating margin	-54,186.2%	Operating Income: -191819000 Open source Revenue: 354000 Open source
20242024-12-31	Operating margin	-5,167.4%	Operating Income: -141018000 Open source Revenue: 2729000 Open source
20252025-12-31	Operating margin	-687.3%	Operating Income: -158330000 Open source Revenue: 23037000 Open source
2020-12-31	Net margin	Not reported	Revenue: 601000 Open source
2021-12-31	Net margin	Not reported	Revenue: 774000 Open source
2022-12-31	Net margin	Not reported	Revenue: 389000 Open source
2023-12-31	Net margin	Not reported	Revenue: 354000 Open source
2024-12-31	Net margin	Not reported	Revenue: 2729000 Open source
2025-12-31	Net margin	Not reported	Revenue: 23037000 Open source
20202020-12-31	Free cash flow margin	-38,994.5%	Revenue: 601000 Open source Operating Cash Flow: -234290000 Open source Capital Expenditure: 67000 Open source
20212021-12-31	Free cash flow margin	Not reported	Revenue: 774000 Open source Operating Cash Flow: -303340000 Open source
20222022-12-31	Free cash flow margin	Not reported	Revenue: 389000 Open source Operating Cash Flow: -288231000 Open source
20232023-12-31	Free cash flow margin	Not reported	Revenue: 354000 Open source Operating Cash Flow: -225101000 Open source
20242024-12-31	Free cash flow margin	-3,288.6%	Revenue: 2729000 Open source Operating Cash Flow: -87943000 Open source Capital Expenditure: 1802000 Open source
20252025-12-31	Free cash flow margin	-564.3%	Revenue: 23037000 Open source Operating Cash Flow: -129872000 Open source Capital Expenditure: 119000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

NOK -129.9M 2025

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(NOK)	Source evidence
20202020-12-31	Operating cash flow	-234290000	Operating Cash Flow: -234290000 Open source
20212021-12-31	Operating cash flow	-303340000	Operating Cash Flow: -303340000 Open source
20222022-12-31	Operating cash flow	-288231000	Operating Cash Flow: -288231000 Open source
20232023-12-31	Operating cash flow	-225101000	Operating Cash Flow: -225101000 Open source
20242024-12-31	Operating cash flow	-87943000	Operating Cash Flow: -87943000 Open source
20252025-12-31	Operating cash flow	-129872000	Operating Cash Flow: -129872000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

NOK -130M 2025

Values and sources

Free cash flow values and source evidence
Period	Series	Value(NOK)	Source evidence
20202020-12-31	Free cash flow	-234357000	Operating Cash Flow: -234290000 Open source Capital Expenditure: 67000 Open source
20212021-12-31	Free cash flow	Unavailable	Operating Cash Flow: -303340000 Open source
20222022-12-31	Free cash flow	Unavailable	Operating Cash Flow: -288231000 Open source
20232023-12-31	Free cash flow	Unavailable	Operating Cash Flow: -225101000 Open source
20242024-12-31	Free cash flow	-89745000	Operating Cash Flow: -87943000 Open source Capital Expenditure: 1802000 Open source
20252025-12-31	Free cash flow	-129991000	Operating Cash Flow: -129872000 Open source Capital Expenditure: 119000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

28.6% 2025

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Liabilities / assets	9.2%	Total Liabilities: 67971000 Open source Total Assets: 738200000 Open source
20212021-12-31	Liabilities / assets	14.6%	Total Liabilities: 65810000 Open source Total Assets: 450236000 Open source
20222022-12-31	Liabilities / assets	46.9%	Total Liabilities: 78208000 Open source Total Assets: 166706000 Open source
20232023-12-31	Liabilities / assets	26.9%	Total Liabilities: 46859000 Open source Total Assets: 174335000 Open source
20242024-12-31	Liabilities / assets	36.7%	Total Liabilities: 62680000 Open source Total Assets: 171015000 Open source
20252025-12-31	Liabilities / assets	28.6%	Total Liabilities: 58634000 Open source Total Assets: 204958000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

3.23× 2025

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Current assets / current liabilities	11.05×	Current Assets: 735869000 Open source Current Liabilities: 66604000 Open source
20212021-12-31	Current assets / current liabilities	6.92×	Current Assets: 449045000 Open source Current Liabilities: 64868000 Open source
20222022-12-31	Current assets / current liabilities	2.14×	Current Assets: 166663000 Open source Current Liabilities: 77933000 Open source
20232023-12-31	Current assets / current liabilities	3.71×	Current Assets: 173904000 Open source Current Liabilities: 46859000 Open source
20242024-12-31	Current assets / current liabilities	2.46×	Current Assets: 142277000 Open source Current Liabilities: 57939000 Open source
20252025-12-31	Current assets / current liabilities	3.23×	Current Assets: 187311000 Open source Current Liabilities: 57959000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2020 2020-01-01 – 2020-12-31	Unavailable Not reported for this period.	−NOK 234.29 million Exact value Exact value: -234290000 NOK 2020-01-01 – 2020-12-31: -234290000 NOK Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Oncoinvent ASA · 2020-12-31 Oncoinvent ASA (esef:213800TYYFXKYF3V2A23) Operating Cash Flow: -234290000 NOK Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-09T13:35:15Z Snapshot: 6eaa3e69e995bfa95c892bf088f139d4f0c61751cb70f2c4c98682d45b353da8 Dimensions: Consolidated View: https://fundies.io/companies/esef/213800TYYFXKYF3V2A23/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=NOK&dimensions= Input fundies:OperatingCashFlow: -234290000 NOK (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/213800TYYFXKYF3V2A23/2021-12-31/ESEF/NO/0/213800TYYFXKYF3V2A23-2021-12-31-en.zip#21135770 Filing: 213800TYYFXKYF3V2A23-2021-12-31-ESEF-NO-0 The citation records this snapshot. The page link may show a newer release later.	NOK 67,000 Exact value Exact value: 67000 NOK 2020-01-01 – 2020-12-31: 67000 NOK Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Oncoinvent ASA · 2020-12-31 Oncoinvent ASA (esef:213800TYYFXKYF3V2A23) Capital Expenditure: 67000 NOK Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-09T13:35:15Z Snapshot: 6eaa3e69e995bfa95c892bf088f139d4f0c61751cb70f2c4c98682d45b353da8 Dimensions: Consolidated View: https://fundies.io/companies/esef/213800TYYFXKYF3V2A23/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=NOK&dimensions= Input fundies:CapitalExpenditure: 67000 NOK (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/213800TYYFXKYF3V2A23/2021-12-31/ESEF/NO/0/213800TYYFXKYF3V2A23-2021-12-31-en.zip#21137595 Filing: 213800TYYFXKYF3V2A23-2021-12-31-ESEF-NO-0 The citation records this snapshot. The page link may show a newer release later.	−NOK 234.36 million Calculation and evidence -234290000 − 67000 NOK Exact free cash flow: -234357000 NOK 2020-01-01 – 2020-12-31: -234290000 NOK · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 67000 NOK · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Oncoinvent ASA · 2020-12-31 Oncoinvent ASA (esef:213800TYYFXKYF3V2A23) Free cash flow: -234357000 NOK Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-09T13:35:15Z Snapshot: 6eaa3e69e995bfa95c892bf088f139d4f0c61751cb70f2c4c98682d45b353da8 Dimensions: Consolidated View: https://fundies.io/companies/esef/213800TYYFXKYF3V2A23?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -234290000 NOK (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/213800TYYFXKYF3V2A23/2021-12-31/ESEF/NO/0/213800TYYFXKYF3V2A23-2021-12-31-en.zip#21135770 Filing: 213800TYYFXKYF3V2A23-2021-12-31-ESEF-NO-0 Input fundies:CapitalExpenditure: 67000 NOK (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/213800TYYFXKYF3V2A23/2021-12-31/ESEF/NO/0/213800TYYFXKYF3V2A23-2021-12-31-en.zip#21137595 Filing: 213800TYYFXKYF3V2A23-2021-12-31-ESEF-NO-0 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	Unavailable Not reported for this period.	−NOK 303.34 million Exact value Exact value: -303340000 NOK 2021-01-01 – 2021-12-31: -303340000 NOK Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Oncoinvent ASA · 2021-12-31 Oncoinvent ASA (esef:213800TYYFXKYF3V2A23) Operating Cash Flow: -303340000 NOK Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-09T13:35:15Z Snapshot: 6eaa3e69e995bfa95c892bf088f139d4f0c61751cb70f2c4c98682d45b353da8 Dimensions: Consolidated View: https://fundies.io/companies/esef/213800TYYFXKYF3V2A23/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=NOK&dimensions= Input fundies:OperatingCashFlow: -303340000 NOK (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/213800TYYFXKYF3V2A23/2022-12-31/ESEF/NO/0/213800TYYFXKYF3V2A23-2022-12-31-en.zip#39154092 Filing: 213800TYYFXKYF3V2A23-2022-12-31-ESEF-NO-0 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2022 2022-01-01 – 2022-12-31	Unavailable Not reported for this period.	−NOK 288.23 million Exact value Exact value: -288231000 NOK 2022-01-01 – 2022-12-31: -288231000 NOK Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Oncoinvent ASA · 2022-12-31 Oncoinvent ASA (esef:213800TYYFXKYF3V2A23) Operating Cash Flow: -288231000 NOK Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-09T13:35:15Z Snapshot: 6eaa3e69e995bfa95c892bf088f139d4f0c61751cb70f2c4c98682d45b353da8 Dimensions: Consolidated View: https://fundies.io/companies/esef/213800TYYFXKYF3V2A23/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=NOK&dimensions= Input fundies:OperatingCashFlow: -288231000 NOK (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/213800TYYFXKYF3V2A23/2023-12-31/ESEF/NO/0/213800TYYFXKYF3V2A23-2023-12-31-en.zip#9734993 Filing: 213800TYYFXKYF3V2A23-2023-12-31-ESEF-NO-0 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2023 2023-01-01 – 2023-12-31	Unavailable Not reported for this period.	−NOK 225.1 million Exact value Exact value: -225101000 NOK 2023-01-01 – 2023-12-31: -225101000 NOK Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Oncoinvent ASA · 2023-12-31 Oncoinvent ASA (esef:213800TYYFXKYF3V2A23) Operating Cash Flow: -225101000 NOK Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-09T13:35:15Z Snapshot: 6eaa3e69e995bfa95c892bf088f139d4f0c61751cb70f2c4c98682d45b353da8 Dimensions: Consolidated View: https://fundies.io/companies/esef/213800TYYFXKYF3V2A23/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=NOK&dimensions= Input fundies:OperatingCashFlow: -225101000 NOK (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/213800TYYFXKYF3V2A23/2024-12-31/ESEF/NO/0/213800TYYFXKYF3V2A23-2024-12-31-0-en.zip#6381418 Filing: 213800TYYFXKYF3V2A23-2024-12-31-ESEF-NO-0 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2024 2024-01-01 – 2024-12-31	Unavailable Not reported for this period.	−NOK 87.94 million Exact value Exact value: -87943000 NOK 2024-01-01 – 2024-12-31: -87943000 NOK Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Oncoinvent ASA · 2024-12-31 Oncoinvent ASA (esef:213800TYYFXKYF3V2A23) Operating Cash Flow: -87943000 NOK Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-09T13:35:15Z Snapshot: 6eaa3e69e995bfa95c892bf088f139d4f0c61751cb70f2c4c98682d45b353da8 Dimensions: Consolidated View: https://fundies.io/companies/esef/213800TYYFXKYF3V2A23/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=NOK&dimensions= Input fundies:OperatingCashFlow: -87943000 NOK (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/213800TYYFXKYF3V2A23/2025-12-31/ESEF/NO/0/213800TYYFXKYF3V2A23-2025-12-31.zip#9898340 Filing: 213800TYYFXKYF3V2A23-2025-12-31-ESEF-NO-0 The citation records this snapshot. The page link may show a newer release later.	NOK 1.8 million Exact value Exact value: 1802000 NOK 2024-01-01 – 2024-12-31: 1802000 NOK Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Oncoinvent ASA · 2024-12-31 Oncoinvent ASA (esef:213800TYYFXKYF3V2A23) Capital Expenditure: 1802000 NOK Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-09T13:35:15Z Snapshot: 6eaa3e69e995bfa95c892bf088f139d4f0c61751cb70f2c4c98682d45b353da8 Dimensions: Consolidated View: https://fundies.io/companies/esef/213800TYYFXKYF3V2A23/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=NOK&dimensions= Input fundies:CapitalExpenditure: 1802000 NOK (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/213800TYYFXKYF3V2A23/2025-12-31/ESEF/NO/0/213800TYYFXKYF3V2A23-2025-12-31.zip#9902420 Filing: 213800TYYFXKYF3V2A23-2025-12-31-ESEF-NO-0 The citation records this snapshot. The page link may show a newer release later.	−NOK 89.75 million Calculation and evidence -87943000 − 1802000 NOK Exact free cash flow: -89745000 NOK 2024-01-01 – 2024-12-31: -87943000 NOK · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 1802000 NOK · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Oncoinvent ASA · 2024-12-31 Oncoinvent ASA (esef:213800TYYFXKYF3V2A23) Free cash flow: -89745000 NOK Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-09T13:35:15Z Snapshot: 6eaa3e69e995bfa95c892bf088f139d4f0c61751cb70f2c4c98682d45b353da8 Dimensions: Consolidated View: https://fundies.io/companies/esef/213800TYYFXKYF3V2A23?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -87943000 NOK (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/213800TYYFXKYF3V2A23/2025-12-31/ESEF/NO/0/213800TYYFXKYF3V2A23-2025-12-31.zip#9898340 Filing: 213800TYYFXKYF3V2A23-2025-12-31-ESEF-NO-0 Input fundies:CapitalExpenditure: 1802000 NOK (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/213800TYYFXKYF3V2A23/2025-12-31/ESEF/NO/0/213800TYYFXKYF3V2A23-2025-12-31.zip#9902420 Filing: 213800TYYFXKYF3V2A23-2025-12-31-ESEF-NO-0 The citation records this snapshot. The page link may show a newer release later.
2025 2025-01-01 – 2025-12-31	Unavailable Not reported for this period.	−NOK 129.87 million Exact value Exact value: -129872000 NOK 2025-01-01 – 2025-12-31: -129872000 NOK Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Oncoinvent ASA · 2025-12-31 Oncoinvent ASA (esef:213800TYYFXKYF3V2A23) Operating Cash Flow: -129872000 NOK Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-09T13:35:15Z Snapshot: 6eaa3e69e995bfa95c892bf088f139d4f0c61751cb70f2c4c98682d45b353da8 Dimensions: Consolidated View: https://fundies.io/companies/esef/213800TYYFXKYF3V2A23/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=NOK&dimensions= Input fundies:OperatingCashFlow: -129872000 NOK (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/213800TYYFXKYF3V2A23/2025-12-31/ESEF/NO/0/213800TYYFXKYF3V2A23-2025-12-31.zip#9898032 Filing: 213800TYYFXKYF3V2A23-2025-12-31-ESEF-NO-0 The citation records this snapshot. The page link may show a newer release later.	NOK 119,000 Exact value Exact value: 119000 NOK 2025-01-01 – 2025-12-31: 119000 NOK Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Oncoinvent ASA · 2025-12-31 Oncoinvent ASA (esef:213800TYYFXKYF3V2A23) Capital Expenditure: 119000 NOK Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-09T13:35:15Z Snapshot: 6eaa3e69e995bfa95c892bf088f139d4f0c61751cb70f2c4c98682d45b353da8 Dimensions: Consolidated View: https://fundies.io/companies/esef/213800TYYFXKYF3V2A23/explain?concept=fundies%3ACapitalExpenditure&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=NOK&dimensions= Input fundies:CapitalExpenditure: 119000 NOK (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/213800TYYFXKYF3V2A23/2025-12-31/ESEF/NO/0/213800TYYFXKYF3V2A23-2025-12-31.zip#9902073 Filing: 213800TYYFXKYF3V2A23-2025-12-31-ESEF-NO-0 The citation records this snapshot. The page link may show a newer release later.	−NOK 129.99 million Calculation and evidence -129872000 − 119000 NOK Exact free cash flow: -129991000 NOK 2025-01-01 – 2025-12-31: -129872000 NOK · Inspect Operating Cash Flow · Source 2025-01-01 – 2025-12-31: 119000 NOK · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Oncoinvent ASA · 2025-12-31 Oncoinvent ASA (esef:213800TYYFXKYF3V2A23) Free cash flow: -129991000 NOK Concept: free-cash-flow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-09T13:35:15Z Snapshot: 6eaa3e69e995bfa95c892bf088f139d4f0c61751cb70f2c4c98682d45b353da8 Dimensions: Consolidated View: https://fundies.io/companies/esef/213800TYYFXKYF3V2A23?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -129872000 NOK (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/213800TYYFXKYF3V2A23/2025-12-31/ESEF/NO/0/213800TYYFXKYF3V2A23-2025-12-31.zip#9898032 Filing: 213800TYYFXKYF3V2A23-2025-12-31-ESEF-NO-0 Input fundies:CapitalExpenditure: 119000 NOK (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://filings.xbrl.org/213800TYYFXKYF3V2A23/2025-12-31/ESEF/NO/0/213800TYYFXKYF3V2A23-2025-12-31.zip#9902073 Filing: 213800TYYFXKYF3V2A23-2025-12-31-ESEF-NO-0 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

5 filings · 272 latest values · 272 originally reported values

Dataset published 2026-11-09. Source filing dates and reporting periods are shown separately.

Identifiers: 213800TYYFXKYF3V2A23, esef:213800TYYFXKYF3V2A23

Oncoinvent ASA

Latest fiscal year

Revenue

Operating margin

Operating cash flow

Free cash flow

Company performance

What changed year over year

Revenue

Operating cash flow

Capital expenditure

Where revenue goes

2025 2025-01-01 – 2025-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation